Presenter: Yuehan Feng
Date: Monday, Sep 18, 2023, 11:45 AM – 1:00 PM
Session: PP01
Presenter: Yuehan Feng
The role of the Extracellular Vesicles (EVs) proteome as a crucial indicator in melanoma progression has long been recognized, but their potential as viable clinical biomarkers has remained relatively unexplored. Moreover, most proteomic techniques are incompatible with characterizing the EVs proteome due to its wide range of protein concentrations.
In a collaborative effort with the University of Zurich, the Université de Fribourg – Universität Freiburg, and Stanford University, we have successfully devised a workflow for isolating blood-derived exosomes and profiling their proteome content using our cutting-edge TrueDiscovery® platform.
Explore the comprehensive workflow for analyzing EVs as potential biomarkers in melanoma progression in our poster.
Presenter: Lukas Reiter
Session: Poster Session B
Date: August 31 and September 1
Presenter: Nigel Beaton
In collaboration with the Parker Institute for Cancer Immunotherapy (PICI)
We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.
Presenter: Marco Tognetti
Date: Wednesday, June 7
Topic area for your poster: Neurodegenerative Disease Research I
Presenter: Yuehan Feng
Date: Tuesday, Sep 19, 2023, 11:45 AM – 1:00 PM
Session: PP03
Presenter: Yuehan Feng
Wednesday, August 17
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
